- Home
- CBAN vs ATAI Comparison
CBAN vs ATAI Comparison
Compare CBAN & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBAN
- ATAI
- Stock Information
- Founded
- CBAN 1975
- ATAI 2018
- Country
- CBAN United States
- ATAI Germany
- Employees
- CBAN N/A
- ATAI N/A
- Industry
- CBAN Major Banks
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- CBAN Finance
- ATAI Health Care
- Exchange
- CBAN Nasdaq
- ATAI Nasdaq
- Market Cap
- CBAN 285.4M
- ATAI 282.6M
- IPO Year
- CBAN 1998
- ATAI 2021
- Fundamental
- Price
- CBAN $15.38
- ATAI $1.47
- Analyst Decision
- CBAN
- ATAI Strong Buy
- Analyst Count
- CBAN 0
- ATAI 3
- Target Price
- CBAN N/A
- ATAI $10.50
- AVG Volume (30 Days)
- CBAN 76.0K
- ATAI 1.7M
- Earning Date
- CBAN 04-23-2025
- ATAI 05-14-2025
- Dividend Yield
- CBAN 3.00%
- ATAI N/A
- EPS Growth
- CBAN 14.66
- ATAI N/A
- EPS
- CBAN 1.43
- ATAI N/A
- Revenue
- CBAN $113,756,000.00
- ATAI $308,000.00
- Revenue This Year
- CBAN $14.62
- ATAI $65.58
- Revenue Next Year
- CBAN $6.49
- ATAI N/A
- P/E Ratio
- CBAN $10.75
- ATAI N/A
- Revenue Growth
- CBAN 3.33
- ATAI N/A
- 52 Week Low
- CBAN $10.68
- ATAI $1.03
- 52 Week High
- CBAN $18.49
- ATAI $2.57
- Technical
- Relative Strength Index (RSI)
- CBAN 50.13
- ATAI 51.16
- Support Level
- CBAN $14.54
- ATAI $1.41
- Resistance Level
- CBAN $15.87
- ATAI $1.56
- Average True Range (ATR)
- CBAN 0.63
- ATAI 0.12
- MACD
- CBAN 0.13
- ATAI 0.03
- Stochastic Oscillator
- CBAN 73.94
- ATAI 75.61
About CBAN Colony Bankcorp Inc.
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.